Fig. 9: Schematic showing transcriptional regulation of DLX1 and therapeutic utility of BET inhibitor and anti-androgen in suppressing DLX1-mediated oncogenic effects. | Nature Communications

Fig. 9: Schematic showing transcriptional regulation of DLX1 and therapeutic utility of BET inhibitor and anti-androgen in suppressing DLX1-mediated oncogenic effects.

From: Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression

Fig. 9: Schematic showing transcriptional regulation of DLX1 and therapeutic utility of BET inhibitor and anti-androgen in suppressing DLX1-mediated oncogenic effects.

Illustration depicting transcriptional regulation of DLX1 via ERG and AR-driven circuitry in ERG fusion-positive background, and through AR/FOXA1 in an ERG-independent context, thereby promoting cancer progression and metastases. In addition, DLX1 drives the expression of its target genes involved in stemness and oncogenesis, such as ALDH1A1 and HNF1A. Utility of BET inhibitor alone or in combination with anti-androgen drugs to target transcriptional regulators of DLX1 resulting in reduced expression of DLX1 and its downstream oncogenesis. Created with BioRender.com.

Back to article page